Elicio Therapeutics (ELTX) Net Cash Flow (2020 - 2026)

Elicio Therapeutics has reported Net Cash Flow for 7 years, with the latest figure at -$3.6 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 1831.1% year-over-year to -$3.6 million; the trailing twelve-month figure through Mar 2026 stood at -$4.1 million (down 163.34% YoY), and the FY2025 full-year result was -$273000.0, down 105.28% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$3.6 million, down from -$2.0 million in the prior quarter.
• The five-year high for Net Cash Flow was $23.5 million in Q3 2024, with the low at -$15.7 million in Q1 2022.
• Historically, Net Cash Flow has averaged $325529.4 across 5 years, with a median of -$1.1 million in 2024.
• Annual changes were most pronounced in 2024 — Net Cash Flow jumped 554.16% — and 2026, when it tumbled 1831.1%.
• Elicio Therapeutics' Net Cash Flow stood at $3.8 million in 2022, then tumbled by 176.06% to -$2.9 million in 2023, then sank by 195.85% to -$8.6 million in 2024, then surged by 77.22% to -$2.0 million in 2025, then plunged by 85.54% to -$3.6 million in 2026.
• The last three Net Cash Flow figures came in at -$3.6 million (Q1 2026), -$2.0 million (Q4 2025), and -$1.5 million (Q3 2025), per Business Quant data.